Drug Trial Radar · NCT04906395
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jul 1, 2021
Primary completion
Jan 30, 2027
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Tolmar Inc.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Period will be conducted in two parts: 1) an abbreviated, initial screening where premenopausal status will be determined prior to neoadjuvant or adjuvant chemotherapy (if planned) and 2) the full screening assessment conducted after neoadjuvant or adjuvant chemotherapy (or for subjects who enter the study without having received chemotherapy). Following the Screening Period, eligible subjects will enter into the 48 week Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506 or those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of \< 20 pg/mL (testosterone levels \< 50 ng/dL in males) have been achieved. After Week 12, subjects will be allowed to switch from receiving an AI to receiving tamoxifen or from tamoxifen to AI at the discretion of the Investigator. However, a switch is not permitted 28 days prior to a dosing visit (eg, Week 24, 36, and 48 where a pre-dose blood sample for PK and PD analysis will be drawn). At the end of the Treatment Period, upon completion of the End of Study Visit (Visit 9, Week 48) subjects may be eligible to participate in a Safety Extension Study under a separate Protocol.
Conditions
- Breast Cancer
Interventions
TOL2506Drug
Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
TamoxifenDrug
20 mg once daily or 10 mg 2 times daily - either tablet or solution
Letrozole TabletsDrug
One 2.5 mg tablet taken orally once daily
Anastrozole TabletsDrug
One 1 mg tablet taken orally once daily
Exemestane TabletsDrug
One 25 mg tablet taken orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Suppression of ovarian functionTime frame: 6 weeks after the first administration of TOL2506
Locations
59 sites in 7 countries. Site status is shown where the registry gives one.
Marin Cancer Care, Inc
Greenbrae, California
Cypress Hematology and Oncology
Parker, Colorado
Mount Sinai Hospital
Chicago, Illinois
Baptist Health Louisville
Louisville, Kentucky
Maryland Oncology Hematology, P.A.
Glenn Dale, Maryland
Nebraska Cancer Specialists
Omaha, Nebraska
Montefiore - Einstein Center for Cancer Care at Montefiore Medical Park
The Bronx, New York
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio
Lankenau Medical Center
Wynnewood, Pennsylvania
Tennessee Oncology, PLLC
Chattanooga, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Texas Oncology-Austin
Austin, Texas
Texas Oncology- Dallas Presbyterian Hospital
Dallas, Texas
Texas Oncology- San Antonio
New Braunfels, Texas
Texas Oncology- Northeast Texas
Tyler, Texas
Texas Oncology- Deke Slayton Cancer Center
Webster, Texas
Seattle Cancer Center Alliance
Seattle, Washington
Hospital Aleman
Buenos Aires, Argentina
Fundacion CENIT
CABA, Argentina
Sanatorio Allende- Sede Nueva Cordoba
Córdoba, Argentina
Hospital Britanico de Buenos Aires
Buenos Aires, Buenos Aires F.D., Argentina
Instituto Oncologico de Cordoba (IONC)
Córdoba, Córdoba Province, Argentina
Centro Privado de RMI Rio Cuarto
Río Cuarto, Córdoba Province, Argentina
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, Santa Fe Province, Argentina
Hospital Provincial del Centenario
Rosario, Santa Fe Province, Argentina
Irmamandade de Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude
Rio de Janeiro, Brazil
Oncocentro Servicos Medicos e Hospitalares Ltda
Fortaleza, Ceará, Brazil
Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
Hospital Araujo Jorge
Goiânia, Goiás, Brazil
Onconeo
Campo Grande, Mato Grosso do Sul, Brazil
Hospital do Cancer de Londrina
Londrina, Paraná, Brazil
Uniao Brasileira de Educacao e Assistencia
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Amor Amazonia
Porto Velho, Rondônia, Brazil
Fundacao Pio XII
Barretos, São Paulo, Brazil
Centro de Estudos e Pesquisas de Hematologia e Oncologia da Faculdade de Medicina do ABC
Santo André, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria
São Paulo, São Paulo, Brazil
Sunnybrook Odette Cancer Centre Clinical Research Program
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.